biotech news today obesity drugs glp-1 Eli Lilly's Pill Shows Promising Weight Loss in New Results Market Overview: GLP-1 Agonists and
Description
In the SURMOUNT-3 and SURMOUNT-4 studies, participants experienced significant weight losses with tirzepatide treatment, marking a mean weight loss of 26.6% and 26.0% over 84 and 88 weeks respectively [93,94]
1 Introduction The success and ever increasing interest in incretin-based therapies and drugs especially sitagliptin, vildagliptin and exenatide depict their immense importance in improving patient outcomes in T2DM (Nasr and Sadek, 2022)
The program also reflects a broader policy priority of increasing access to high-value treatments while controlling healthcare costs
Most users experience bloating, gas, or temporary digestive changes during the initial adjustment period
